Loading viewer...
investor_presentation
Format: PDF investor_presentation
1stQuarter Fiscal 2022 Earnings Slide Deck
1stQuarter Fiscal 2022 Earnings Slide DeckSafe-Harbor Statement
This presentation contains forward- looking statements that are subject to risks and
uncertainties, and which reflect management’s current beliefs and estimates of future
economic circumstances, industry conditions, Company performance, financial results and
planned financing. You can find a discussion of many of these risks and uncertainties in the annual, quarterly and current reports that the Company files with the Securities and Exchange Commission.
Investors should understand that a number of factors (including but not limited to the
lingering effects of the COVID- 19 pandemic and related public health measures on plant
operations, workforce availability, supply chain availability, and product demand) could cause
future economic and industry conditions and the Company’s actual financial condition and results of operations to differ materially from management’s beliefs expressed in the forward-
looking statements contained in this presentation. These factors include those outlined in
the “Risk Factors” section of the Company’s most recent annual report on Form 10- K filed
with the Securities and Exchange Commission, and investors are urged to review these
factors when considering the forward- looking statements contained in this presentation.
For these statements, the Company claims the protection of the safe harbor for forward-
looking statements contained in the Private Securities Litigation Reform Act of 1995.
For full financial statement information, please see the Company’s earnings release dated
2First Quarter Summary
3•Revenues increased $57.7 million compared to prior year
•Irrigation increased $58.6 million
•Infrastructure decreased $0.9 million
•Operating income increased $5.8 million compared to prior year
•Irrigation increased $6.6 million
•Infrastructure decreased $1.5 million
•Corporate expense decreased $0.7 million
•Operating income reduced by LIFO impact of $6.0 million
•Net earnings reduced by after -tax LIFO impact of $4.5 million, or $0.41 per diluted share Amounts in millions, except per share amounts
Revenue Operating Income Diluted EPS
+53% +11% +77%$166.2
FY21 FY22First Quarter Financial Summary
4($ in millions, except per share amounts) Q1 - FY22 Q1 - FY21 Change
Preview truncated — download the full document for the complete content.
investor_presentation
16 Pages
investor_presentation
33 Pages
Mural Oncology
Regeneron Pharmaceuticals Investor Presentation — June 2021
investor_presentationinvestor_presentation
26 Pages
Regeneron Pharmaceuticals, Inc.